Profile data is unavailable for this security.
About the company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
- Revenue in USD (TTM)13.31m
- Net income in USD-809.24m
- Incorporated2014
- Employees750.00
- LocationRoivant Sciences Ltd7Th Floor, 50 BroadwayLONDON SW1H 0DBUnited KingdomGBR
- Phone+44 12955950
- Websitehttp://roivant.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.03bn | 2.80k | -- | 2.53 | 31.55 | 2.41 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.11bn | 3.04k | 21.67 | 1.83 | 18.41 | 3.59 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.28bn | 391.00 | -- | 5.67 | -- | 540.49 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.34bn | 9.00k | 346.69 | 1.83 | 17.47 | 2.69 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| Neurocrine Biosciences Inc | 2.68bn | 428.00m | 13.91bn | 1.80k | 33.32 | 4.63 | 30.40 | 5.19 | 4.19 | 4.19 | 26.25 | 30.13 | 0.6878 | 0.7611 | 4.44 | 1,490,389.00 | 10.97 | 10.41 | 12.71 | 12.71 | 98.37 | 98.47 | 15.95 | 15.71 | 3.27 | -- | 0.00 | -- | 24.81 | 24.48 | 36.68 | 55.94 | 20.97 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 13.93bn | 725.00 | -- | -- | -- | 39.38 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Moderna Inc | 2.23bn | -3.12bn | 16.39bn | 5.80k | -- | 1.76 | -- | 7.34 | -8.05 | -8.05 | 5.76 | 23.86 | 0.1598 | 2.19 | 1.71 | 384,827.60 | -22.31 | 13.72 | -25.91 | 18.76 | 63.49 | 76.34 | -139.61 | 23.74 | 3.73 | -- | 0.0061 | 0.00 | -52.75 | 121.86 | 24.46 | -- | 101.61 | -- |
| Viatris Inc | 14.12bn | -3.69bn | 17.92bn | 32.00k | -- | 1.19 | -- | 1.27 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Roivant Sciences Ltd | 13.31m | -809.24m | 19.80bn | 750.00 | -- | 4.60 | -- | 1,487.86 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| United Therapeutics Corp | 3.13bn | 1.27bn | 20.37bn | 1.31k | 17.91 | 3.08 | 15.04 | 6.51 | 26.41 | 26.41 | 64.94 | 153.61 | 0.4323 | 2.21 | 9.78 | 2,397,242.00 | 17.57 | 13.61 | 19.48 | 14.84 | 88.59 | 90.79 | 40.65 | 37.81 | 6.07 | -- | 0.00 | 0.00 | 23.63 | 14.71 | 21.35 | -- | 24.11 | -- |
| Incyte Corp | 4.81bn | 1.19bn | 21.41bn | 2.62k | 18.43 | 4.60 | 16.71 | 4.45 | 5.91 | 5.91 | 23.91 | 23.71 | 0.8487 | 4.09 | 5.82 | 1,839,169.00 | 20.96 | 6.35 | 27.96 | 7.89 | 93.47 | 94.43 | 24.69 | 9.56 | 3.13 | -- | 0.0076 | 0.00 | 14.76 | 14.46 | -94.54 | -40.76 | 2.02 | -- |
| Royalty Pharma plc | 2.35bn | 764.96m | 25.43bn | 99.00 | 25.19 | 3.98 | 29.16 | 10.82 | 1.75 | 1.75 | 4.11 | 11.08 | 0.1257 | -- | 87.35 | 23,735,800.00 | 6.97 | 7.56 | 8.95 | 10.21 | -- | -- | 55.43 | 55.06 | -- | 6.91 | 0.4818 | 46.51 | -3.86 | 4.52 | -24.31 | -18.22 | 7.80 | -- |
| Biogen Inc | 9.89bn | 1.29bn | 28.44bn | 7.50k | 22.01 | 1.56 | 13.72 | 2.88 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
Data as of Feb 10 2026. Currency figures normalised to Roivant Sciences Ltd's reporting currency: US Dollar USD
42.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 60.70m | 8.73% |
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2025 | 40.20m | 5.78% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 38.77m | 5.58% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 35.76m | 5.14% |
| QVT Financial LPas of 17 Dec 2025 | 26.39m | 3.79% |
| Viking Global Investors LPas of 30 Sep 2025 | 23.59m | 3.39% |
| Rubric Capital Management LPas of 30 Sep 2025 | 20.00m | 2.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 18.70m | 2.69% |
| UBS Securities LLCas of 31 Dec 2025 | 17.18m | 2.47% |
| Two Seas Capital LPas of 30 Sep 2025 | 11.75m | 1.69% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
